EyePoint

Q2 FY2026 EarningsFY26 Q3 results were overshadowed by the Phase 3 LUCIA study failure in wet AMD, leading to a massive strategic pivot. The company reported cash and equivalents of $118M as of September 30, 2026, while announcing a 53% workforce reduction and the termination of wet AMD trials to preserve capital. Guidance now focuses entirely on the DURAVYU DME program with a pivotal readout delayed until Q4 2027.